Glenmark Pharmaceuticals secures ANDA Nod for 0.03 per cent Tacrolimus Ointment

This ointment is the 0.03 percent generic version of Leo Pharma AS's Protopic1 ointment. Glenmark Pharmaceuticals Inc., USA will oversee the distribution of Glenmark's Tacrolimus ointment, 0.03 percent, in the United States. Glenmark Pharmaceuticals Ltd., a pharmaceutical company, has received final approval from the United States Food and Drug Administration (USFDA) for its 0.03 percent Tacrolimus ointment. This ointment is the 0.03 percent generic version of Leo Pharma AS's Protopic1 ointment. Glenmark Pharmaceuticals Inc., USA will oversee the distribution of Glenmark's Tacrolimus ointment, 0.03 percent, in the United States. According to recent IQVIATM sales statistics covering the 12-month period ending in June 2023, the market for Protopic® Ointment, 0.03 percent, achieved annual sales of roughly $15.4 million. Glenmark's current product line includes 184 goods that have been approved for distribution in the United States. In addition, the company has 51 Abbreviated New Drug Applications (ANDAs) pending FDA approval.